Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Skeletal consequences of thiazolidinedione therapy.

Grey A.

Osteoporos Int. 2008 Feb;19(2):129-37. Epub 2007 Sep 28. Review.

PMID:
17901911
2.

Thiazolidinedione-induced skeletal fragility--mechanisms and implications.

Grey A.

Diabetes Obes Metab. 2009 Apr;11(4):275-84. doi: 10.1111/j.1463-1326.2008.00931.x. Epub 2008 Jul 29. Review.

PMID:
18671797
3.

[Thiazolidinediones and skeletal health].

Meier C, Bodmer M, Meier CR, Kraenzlin ME.

Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Review. French.

PMID:
19626930
4.

Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.

Schwartz AV, Sellmeyer DE.

Expert Opin Drug Saf. 2008 Jan;7(1):69-78. doi: 10.1517/14740338.7.1.69 . Review.

PMID:
18171315
5.

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC.

J Endocrinol. 2004 Oct;183(1):203-16.

6.

Bone as a target of type 2 diabetes treatment.

Lecka-Czernik B.

Curr Opin Investig Drugs. 2009 Oct;10(10):1085-90. Review.

PMID:
19777397
7.

The role of PPARγ for the osteoblastic differentiation.

Viccica G, Francucci CM, Marcocci C.

J Endocrinol Invest. 2010;33(7 Suppl):9-12. Review.

PMID:
20938219
8.

Diabetes and skeletal health.

Yaturu S.

J Diabetes. 2009 Dec;1(4):246-54. doi: 10.1111/j.1753-0407.2009.00049.x. Epub 2009 Aug 17. Review.

9.

[Overview: derangement of bone metabolism in diabetes mellitus].

Takeuchi Y.

Clin Calcium. 2009 Sep;19(9):1247-55. doi: CliCa090912471255. Review. Japanese.

PMID:
19721195
10.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
11.

Insulin resistance and PPAR insulin sensitizers.

Bhatia V, Viswanathan P.

Curr Opin Investig Drugs. 2006 Oct;7(10):891-7. Review.

PMID:
17086933
12.

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

Lecka-Czernik B.

Curr Osteoporos Rep. 2010 Dec;8(4):178-84. doi: 10.1007/s11914-010-0027-y. Review.

13.

PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.

Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2012 Jun;10(2):124-34. Review.

PMID:
22471957
14.

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.

Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE.

Transl Res. 2013 Mar;161(3):145-55. doi: 10.1016/j.trsl.2012.08.006. Epub 2012 Sep 27.

15.

Thiazolidinedione safety.

Kung J, Henry RR.

Expert Opin Drug Saf. 2012 Jul;11(4):565-79. doi: 10.1517/14740338.2012.691963. Epub 2012 May 22. Review.

PMID:
22616948
16.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
17.
18.

Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.

Gustafson B, Eliasson B, Smith U.

Diabetologia. 2010 Mar;53(3):536-40. doi: 10.1007/s00125-009-1615-1. Epub 2009 Nov 27.

PMID:
19943155
19.

[Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].

Okazaki R.

Clin Calcium. 2008 Aug;18(8):1154-61. doi: CliCa080811541161. Review. Japanese.

PMID:
18677054
20.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147

Supplemental Content

Support Center